Peptide Policy Watch

This week in peptide policy: October 19–25, 2026

By · Published

A row of seven calendar cards for October 19 to 25, 2026, with Thursday the 22nd marked and a note that no new FDA rule or notice on peptides was found that week.

Not medical advice, and the site owner isn't a medical professional. Nothing here is a recommendation to use any substance. Facts are as of October 25, 2026, and sources with retrieval dates are at the bottom.

Key facts (from the sources below)

  • We found no new FDA rule, final determination, warning letter or advisory-committee notice on peptides or compounded GLP-1 drugs this week (October 19–25, 2026).
  • OIRA, part of the White House Office of Management and Budget, lists a review titled "Interim Access Policy for Compounding Using Certain Peptides" from HHS/FDA, with a received date of 10/14/2026. The page contains no policy text.
  • OIRA's public log shows a meeting about the interim policy dated 10/23/2026 at 2:00 PM, with Hims & Hers Health listed as the requestor.
  • [S] Per a court-docket aggregator, Hims & Hers filed a motion to dismiss the FTC's July lawsuit on October 22, with a hearing set for January 7, 2027. We did not open the filing.
  • FDA's early-announcement page says it "will host an advisory committee meeting before the end of February 2027." The page is marked current as of 04/15/2026, so it is not new this week.
  • We found no final determination on semaglutide, tirzepatide or liraglutide.

[S] = reported by a secondary source and not confirmed in a primary document we read.

What this means in plain English

  • A government log entry that a policy is under review is not a policy. It does not tell us what the policy says, who it would cover or when it would start.
  • A committee recommendation, even if reported accurately, is not an FDA decision.
  • A quiet week means we found nothing public and official that qualified, not that nothing is happening.

Did you miss a big peptide announcement this week? Probably not. This was a quiet week for official peptide and compounding actions. We checked FDA's news feeds, the FDA compounding pages, the Federal Register, SEC filings, ClinicalTrials.gov and the FTC. We found no new FDA rule, final determination, warning letter or advisory-committee notice on peptides or compounded GLP-1 drugs. The one court development was a motion to dismiss in the FTC's case against Hims & Hers, filed October 22. The most useful developments were small: a government record of when a reported peptide policy reached White House review, and an FDA page showing what its next advisory committee meeting is expected to cover.

The week in order

  • October 14 (before the week): the Office of Information and Regulatory Affairs (OIRA), part of the White House Office of Management and Budget, lists a review titled "Interim Access Policy for Compounding Using Certain Peptides," from HHS/FDA, with a received date of 10/14/2026 (OMB review page).
  • October 19: Novo Nordisk filed a Form 6-K with the SEC. It reports share repurchases only.
  • October 21: a pharmacy recalled compounded veterinary medications for potential potency issues. FDA lists the product type as "Animal & Veterinary Drugs." It does not involve peptides or GLP-1s.
  • October 22–23: FDA updated its table of registered 503B outsourcing facilities ("Updated as of 10/22/2026"). This is a routine register, not a policy change.
  • October 22: per a court-docket aggregator, Hims & Hers filed a motion to dismiss the FTC's July lawsuit, with a hearing set for January 7, 2027 (secondary source; we did not open the filing). See our telehealth explainer.
  • October 23: OIRA's public log shows a meeting about the interim policy dated 10/23/2026 at 2:00 PM, with Hims & Hers Health listed as the requestor.

How this changes our cornerstone timeline

Our cornerstone timeline described the interim policy only through news reports. This week we found a primary record. OIRA's page shows the policy's title, an HHS/FDA agency listing, a "Notice" stage, no legal deadline, "Economically Significant: No," and the 10/14/2026 received date. That confirms one narrow fact: the review exists and began October 14. It does not move the policy itself. The page contains no policy text, no list of covered peptides and no conditions. What the policy would do remains unconfirmed. Our timeline first gave October 15, the news-report date, as the date of the White House review. OIRA's received date is a day earlier, and we corrected the timeline today (see our corrections page).

Second, the FDA committee page adds detail to the "GHK-Cu consult" item that our timeline first carried. FDA's early-announcement page says it "will host an advisory committee meeting before the end of February 2027." The agenda has five candidates for the 503A bulks list: GHK-Cu, PEG-MGF, melanotan II, dihexa acetate and LL-37 (cathelicidin). The page says the time and location "will be scheduled in the coming months," and promises a Federal Register notice and a public docket. The page is marked current as of 04/15/2026, so it is not new this week. It shows that on FDA's own page the next meeting is not GHK-Cu only, and we updated the timeline to say so. Our Federal Register searches for documents published since October 1 found no meeting notice. New this week on the site: a GHK-Cu explainer and a comparison of approved and wellness peptides.

Third, the standing items did not move. The 503A category list PDF still reads "Updated May 14, 2026." The Category 2 page is still current as of 04/22/2026. The 503A bulks page is current as of 05/14/2026. The 503B bulks page is current as of 01/07/2025, which is the first reading we have of that page. Our Federal Register search for the 503B clinical-need notices since April 1 returned two documents: the May 1 proposal (91 FR 23431) and the June 26 comment extension (91 FR 38719), which set July 30, 2026 as the comment deadline. We found no final determination on semaglutide, tirzepatide or liraglutide. FTC v. Hims & Hers is still listed as "Pending" on the FTC's case page, which was last updated August 31, 2026 and does not show the October 22 motion.

Still pending

What is still pending

  1. A final 503B determination on the three GLP-1 drugs. We found no final document, and we will keep checking for one.
  2. FDA's response to the July 23–24 committee meeting. FDA's briefing document proposed leaving all seven peptides off the 503A bulks list. AJMC reported that the committee recommended six of the seven anyway, including 8–6 votes with one abstention for BPC-157, KPV and TB-500. This is reported by AJMC, not confirmed in an FDA primary document. We found no FDA minutes or vote summary on the meeting page. AJMC added that FDA still has to decide whether to adopt the committee's nonbinding advice and then finish rulemaking.
  3. The interim policy text, still at White House review as far as the OIRA record shows.
  4. The next advisory committee meeting, which has no date yet.

What to watch

What to watch next week

  • Whether OIRA's entry changes from pending review, and whether any FDA or HHS document with the policy text appears.
  • A Federal Register notice and docket for the committee meeting expected before the end of February 2027.
  • Whether FDA's committee calendar lists a new compounding meeting. We could not read its meeting table this week because it did not load.

What this does not mean

What this does not mean

A government log entry that a policy is under review is not a policy. It does not tell us what the policy says, who it would cover or when it would start. A committee recommendation, even if reported accurately, is not an FDA decision. Leaving Category 2 is not an approval. A quiet week means we found nothing public and official that qualified, not that nothing is happening. We make no claim about whether any substance is safe or effective.

Sources (all retrieved October 25, 2026)

  1. OIRA, Pending EO 12866 Regulatory Review, RIN 0910-ZD94 — https://www.reginfo.gov/public/do/eoDetails?rrid=1568964
  2. OIRA, EO 12866 meeting record, 10/23/2026 — https://www.reginfo.gov/public/do/viewEO12866Meeting?meetingId=1588573&viewRule=true
  3. FDA, Pharmacy Compounding Advisory Committee early announcement, content current as of 04/15/2026 — https://www.fda.gov/advisory-committees/pharmacy-compounding-advisory-committee/meeting-pharmacy-compounding-advisory-committee
  4. FDA, July 23–24, 2026 PCAC meeting page — https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026
  5. FDA, PCAC briefing document (introduction) — https://www.fda.gov/media/193342/download
  6. FDA, 503A category list (PDF), "Updated May 14, 2026" — https://www.fda.gov/media/94155/download
  7. FDA, Category 2 page, current as of 04/22/2026 — https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
  8. FDA, 503A bulks page, current as of 05/14/2026 — https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act
  9. FDA, 503B bulks page, current as of 01/07/2025 — https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503b-fdc-act
  10. FDA, Registered Outsourcing Facilities, updated as of 10/22/2026 — https://www.fda.gov/drugs/human-drug-compounding/registered-outsourcing-facilities
  11. FDA, veterinary compounded-drug recall, Oct. 21, 2026 — https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/wedgewood-pharmacy-issues-recall-certain-compounded-veterinary-medications-within-expiry-due
  12. Federal Register API search results (FR 2026-08552, 2026-12937) — https://www.federalregister.gov/api/v1/documents.json
  13. SEC, Novo Nordisk Form 6-K, Oct. 19, 2026 — https://www.sec.gov/Archives/edgar/data/353278/000117184326006685/f6k_101926.htm
  14. FTC, Hims & Hers case page (Pending; last updated Aug. 31, 2026) — https://www.ftc.gov/legal-library/browse/cases-proceedings/hims-hers
  15. AJMC (secondary), July 31, 2026 — https://www.ajmc.com/view/fda-panel-backs-6-peptides-for-compounding
  16. PacerMonitor (secondary; mirrors the court docket), N.D. Cal. 3:26-cv-07871, docket last updated 10/23/2026 — https://www.pacermonitor.com/public/case/65961048/Federal_Trade_Commission_et_al_v_Hims__Hers_Health,_Inc

Spot a mistake? See how we source and our corrections policy.